<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629208</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-497-6486</org_study_id>
    <secondary_id>2022-501523-24-00</secondary_id>
    <nct_id>NCT05629208</nct_id>
  </id_info>
  <brief_title>Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)</brief_title>
  <official_title>A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be&#xD;
      useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information&#xD;
      on what is happening in the body relating to CLE, how the body processes, is affected by and&#xD;
      responds to the study drug, and any study drug side effects will also be collected in this&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The CLASI is a standardized, validated measure of cutaneous lupus disease activity and damage, widely used in clinical trials. CLASI consists of CLASI - activity (A) and - damage (D) measurements. CLASI-A scores range from 0 to 70, with higher scores indicating more severe disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Cutaneous Lupus Activity Investigator Global Assessment (CLA-IGA) Score of 0 or 1 at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The CLA-IGA is a measure of cutaneous lupus erythematosus (CLE) activity and will be recorded on a scale of 0 to 4, with 0 indicating &quot;clear&quot; and 4 indicating &quot;severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>First dose date up to 12 weeks plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Serious Treatment-emergent Adverse Events (TESAEs)</measure>
    <time_frame>First dose date up to 12 weeks plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Laboratory Abnormalities</measure>
    <time_frame>First dose date up to 12 weeks plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Edecesertib</measure>
    <time_frame>Postdose at Week 2, Predose at Week 4 and 12, and Week 8 (anytime of the day)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Cutaneous Lupus Erythematosus (CLE)</condition>
  <arm_group>
    <arm_group_label>Edecesertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive edecesertib 30 mg, once daily starting on Day 1 for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edecesertib Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive edecesertib placebo, once daily starting on Day 1 for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edecesertib</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Edecesertib</arm_group_label>
    <other_name>GS-5718</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edecesertib Placebo</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Edecesertib Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Either fulfill European League Against Rheumatism/American College of Rheumatology&#xD;
             (EULAR/ACR) 2019 classification criteria for systemic lupus erythematosus (SLE) and/or&#xD;
             have biopsy confirmed Cutaneous Lupus Erythematosus (CLE) at any time.&#xD;
&#xD;
          -  Must have active CLE at screening and Day 1. Individuals with acute CLE (ACLE) must&#xD;
             have involvement of 2 distinct body areas.&#xD;
&#xD;
          -  Cutaneous Lupus Erythematosus Disease Area and Severity Index activity - A (CLASI-A)&#xD;
             score (excluding alopecia) of ≥ 8 and CLASI-A erythema score of ≥ 4 during screening&#xD;
             and on Day 1. Individuals with SLE must have Systemic Lupus Erythematosus Disease&#xD;
             Activity Index 2000 (SLEDAI-2K) score of ≥ 4 at screening.&#xD;
&#xD;
          -  Presence of at least 1 representative lupus skin lesion amenable to punch biopsy and&#xD;
             individual willingness to undergo skin punch biopsy at 2 time points.&#xD;
&#xD;
          -  Must have documented prior intolerance or inadequate response at any time (per&#xD;
             investigator judgement) to protocol-specified treatments.&#xD;
&#xD;
               -  Topical corticosteroids or topical calcineurin inhibitors.&#xD;
&#xD;
               -  Oral corticosteroids.&#xD;
&#xD;
               -  Any other nonbiologic standard-of-care therapy, including, but not limited to:&#xD;
                  chloroquine, quinacrine, hydroxychloroquine, azathioprine, mycophenolate mofetil&#xD;
                  (MMF), leflunomide, dapsone, or methotrexate (MTX).&#xD;
&#xD;
          -  Individuals willing to comply with all study visits and assessments.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with only chilblains lupus, lupus panniculitis, lupus tumidus and/or&#xD;
             localized acute CLE involving only 1 distinct body area at screening and Day 1.&#xD;
&#xD;
          -  Have highly active SLE (including but not limited to lupus nephritis, neuropsychiatric&#xD;
             SLE, and/or vasculitis).&#xD;
&#xD;
          -  Presence of active skin conditions other than cutaneous lupus that may interfere with&#xD;
             assessing lupus-specific skin lesion(s) (eg, psoriasis, and/or drug-induced lupus).&#xD;
&#xD;
          -  Meet protocol-specified infection or lab criteria.&#xD;
&#xD;
               -  Any active infection that is clinically significant (per investigator judgment).&#xD;
&#xD;
          -  Any history of clinically significant liver disease.&#xD;
&#xD;
          -  Significant cardiovascular disease.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gileadclinicaltrials.com/study/?id=GS-US-497-6486</url>
    <description>Gilead Clinical Trials Website</description>
  </link>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>April 21, 2023</last_update_submitted>
  <last_update_submitted_qc>April 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

